A pilot study on effects of combination usage of curcumin and melatonin on cisplatin treatment
| dc.contributor.author | Özdatlı, Şükran | |
| dc.contributor.author | Kaşıkçıoğlu, G. | |
| dc.contributor.author | Göçmen, Emrah | |
| dc.contributor.author | Rüzgar, Melih | |
| dc.contributor.author | Omurtag, Gülden Zehra | |
| dc.date.accessioned | 10.07.201910:49:13 | |
| dc.date.accessioned | 2019-07-10T20:03:19Z | |
| dc.date.available | 10.07.201910:49:13 | |
| dc.date.available | 2019-07-10T20:03:19Z | |
| dc.date.issued | 2016 | |
| dc.department | İstanbul Medipol Üniversitesi, Eczacılık Fakültesi, Eczacılık Meslek Bilimleri Bölümü, Farmasötik Toksikoloji Ana Bilim Dalı | |
| dc.description | 52nd Congress of the European-Societies-of-Toxicology (EUROTOX) -- SEP 04-07, 2016 -- Seville, SPAIN | |
| dc.description | WOS: 000402436700390 | |
| dc.description.abstract | Cisplatin is an antitumor drug widely used in the treatmentof many malignant tumors. And also some studies show thatmelatonin and curcumin have antitumor activity via several mech-anisms including theirs in addition to theirs potent antioxidantactions. This study was performed to evaluate the effect of cur-cumin and melatonin on the cytotoxicity induced by cisplatin inthe human breast cancer cell line (MCF-7). The cells were treatedwith melatonin or cisplatin or curcumin for 24 and 48 h. Cellviability was quantified using the 3-(4,5-dimethyl-2-thiazolyl)- | |
| dc.description.sponsorship | European Society of Toxicologic | en_US |
| dc.identifier.citation | Özdatlı, Ş., Kaşıkçıoğlu G., Göçmen, E., Rüzgar, M. ve Omurtag, G. (2016). A pilot study on effects of combination usage of curcumin and melatonin on cisplatin treatment. 52nd Congress of the European-Societies-of-Toxicology (EUROTOX) içinde (S132-S133. ss.). Seville, Spain, September 04-07, 2016. https://dx.doi.org/10.1016/j.toxlet.2016.06.1522 | |
| dc.identifier.doi | 10.1016/j.toxlet.2016.06.1522 | |
| dc.identifier.endpage | S133 | |
| dc.identifier.issn | 0378-4274 | |
| dc.identifier.issn | 1879-3169 | |
| dc.identifier.issue | Supplement: S | |
| dc.identifier.startpage | S132 | |
| dc.identifier.uri | https://dx.doi.org/10.1016/j.toxlet.2016.06.1522 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12511/3849 | |
| dc.identifier.volume | 258 | |
| dc.identifier.wosquality | Q2 | |
| dc.indekslendigikaynak | Web of Science | |
| dc.language.iso | en | |
| dc.publisher | Elsevier Ireland Ltd | |
| dc.relation.ispartof | 52nd Congress of the European-Societies-of-Toxicology (EUROTOX) | en_US |
| dc.relation.publicationcategory | Konferans Öğesi - Uluslararası - Kurum Öğretim Elemanı | |
| dc.rights | info:eu-repo/semantics/embargoedAccess | |
| dc.subject | Pharmacy | |
| dc.subject | Pharmaceutical Toxicology | |
| dc.title | A pilot study on effects of combination usage of curcumin and melatonin on cisplatin treatment | |
| dc.type | Conference Object |
Dosyalar
Orijinal paket
1 - 1 / 1
Küçük Resim Yok
- İsim:
- Özdatlı, Ş..pdf
- Boyut:
- 88.66 KB
- Biçim:
- Adobe Portable Document Format
- Açıklama:
- Tam Metin / Full Text











